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DAbstractEbolavirus and Marburgvirus (belonging to the Filoviridae family) emerged four decades ago and cause epidemics of
haemorrhagic fever with high case-fatality rates. The genome of filoviruses encodes seven proteins. No significant homol-
ogy is observed between filovirus proteins and any known macromolecule. Moreover, Marburgvirus and Ebolavirus show
significant differences in protein homology. The natural maintenance cycle of filoviruses is unknown, the natural reservoir,
the mode of transmission, the epidemic disease generation, and temporal dynamics are unclear. Lastly, Ebolavirus and
Marburgvirus are considered as potential biological weapons. Vaccine appears the unique therapeutic frontier. Here,
molecular and clinical aspects of filoviral haemorrhagic fevers are summarized.
 2007 Published by Elsevier Ltd.
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1. Introduction
Mononegavirales, or ‘non-segmented negative-strand RNA viruses’, are enveloped viruses that have gen-
omes consisting of a single-strand RNA (ssRNA) molecule of negative sense. The Mononegavirales order
includes the Rhabdoviridae, Paramyxoviridae, Filoviridae, and Bornaviridae families. Although these viruses,
of high medical and economical relevance, have different hosts and distinct morphological and biological
properties, the typical mode of replication and gene expression has been retained. This suggests that they have
originated from a common ancestor (see Conzelmann, 2004).
Ebolavirus and Marburgvirus are two genera of negative-sense ssRNA viruses, which together make up the
family Filoviridae. Nowadays, there are five known species of filovirus (Zaire ebolavirus, Sudan ebolavirus,
Ivory Coast ebolavirus, Reston ebolavirus, and Lake Victoria marburgvirus) and nineteen recognised strains
(thirteen of Ebolavirus and six of Marburgvirus) (Table 1) (http://www.ncbi.nlm.nih.gov/ICTVdb/ICTVdB).
The family name comes from the Latin filum, meaning ‘thread’ or ‘filament’, reflecting the morphology of the
virus particles on electron microscopy. The names ‘Ebola’ and ‘Marburg’ come from the river Ebola, in Sudan
and Zaire, where one of the first registered outbreaks of the disease occurred and from the town of Marburg,
in Germany, where the first known outbreaks of Filoviridae diseases occurred and where Filoviridae have been
discovered (see Feldmann and Klenk, 1996; Pigott, 2005).
Marburgvirus and Ebolavirus cause severe haemorrhagic illness in humans, for which there is no effective
specific treatment (see Takada and Kawaoka, 2001; Mahanty and Bray, 2004; Pigott, 2005; Hoenen et al.,
2006a). Marburgvirus was identified in 1967 when imported non-human primates introduced the agent to sev-
eral European vaccine production facilities (Siegert et al., 1967). Ebolavirus was recognised in Central Africa in
1976 (Johnson et al., 1977), and all the outbreaks have occurred in that region (see Mahanty and Bray, 2004)
(Fig. 1). The natural reservoir, the mode of transmission to hominids and pongids, the epidemic diseases gen-
eration, and temporal dynamics remain unclear. Plants, arthropods, reptiles, and small mammals (e.g., bats and
rodents) are potential reservoirs (see Arata and Johnson, 1978; Germain, 1978; Murphy and Peters, 1998; Leirs
et al., 1999; Isaa¨cson, 2001; Feldmann et al., 2004; Peterson et al., 2004a; Leroy et al., 2005; Wong et al., 2007).
Recent resurgence in research, fuelled by funding generated by the fear that filoviruses would make effective
biological weapons (see Borio et al., 2002; Bray, 2003; Leffel and Reed, 2004; Salvaggio and Baddley, 2004;
Paragas and Geisbert, 2006; Hoenen et al., 2006a), has led to a better understanding of the viruses and to
the development of countermeasures including vaccines (see Feldmann et al., 2003, 2005; Geisbert and Jahr-
ling, 2003; Hensley et al., 2005; Warfield et al., 2005; Paragas and Geisbert, 2006; Stroher and Feldmann,
2006; Bausch and Geisbert, 2007).
Here, molecular and clinical aspects of filoviral haemorrhagic fevers are summarized.se cite this article in press as: Ascenzi, P. et al., Ebolavirus and Marburgvirus: Insight the Filoviridae family, Mo-
ar Aspects of Medicine (2007), doi:10.1016/j.mam.2007.09.005
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Fig. 1. Map of Ebola outbreaks in Africa. Bumba (s), Maridi and Yambio (d), Kikwit (.), Tai Forest (m), and Gabon (n). Modified
from http://virus.stanford.edu/filo/history.html.
Table 1
Species and strains of the Genus Ebolavirus and Marburgvirusa
Species Strains
Ivory Coast ebolavirus Ivory Coast (Tai Forest, 1994)
Reston ebolavirus Reston (1989)
Philippine (1989)
Siena (1992)
Texas (1996)
Sudan ebolavirus Boniface (1976)
Maleo (1979)
Zaire ebolavirus Eckron (Zaire, 1976)
Gabon (Zaire, 1994–1997)
Kikwit (Zaire, 1995)
Mayinga (Zaire, 1976)
Tandala (Zaire, 1977)
Zaire (Zaire, 1976)
Lake Victoria marburgvirus Marburg Ravn (Kenya, 1987)
Musoke (Kenya, 1980)
Ozolin (Zimbabwe, 1975)
Popp (West Germany, 1967)
Ratayczak (West Germany, 1967)
Voege (Yugoslavia, 1967)
a Modified from http://www.ncbi.nlm.nih.gov/ICTVdb/ICTVdB.
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2. Filovirus structure
2.1. The virion
Filovirus virions have a complex construction and consist of an envelope, a nucleocapsid, a polymerase
complex, and a matrix. Virions are enveloped, filamentous, or pleomorphic with extensive branching orPlease cite this article in press as: Ascenzi, P. et al., Ebolavirus and Marburgvirus: Insight the Filoviridae family, Mo-
lecular Aspects of Medicine (2007), doi:10.1016/j.mam.2007.09.005
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U-shaped or 6-shaped, about 80 nm in diameter, greatly variable up to 1400 nm long (Fig. 2). The surface pro-
jections are distinctive knob-shaped peplomers evenly covering the surface. They are spaced widely apart,
evenly dispersed and embedded in a lipid bilayer. The surface projections comprise surface glycoproteins
(GPs) and are composed of one type of protein. Surface projections are 10 nm long and spaced 10 nm apart.
The nucleocapsid exhibits helical symmetry, is cross-striated, and is 50 nm in diameter. Axial canal is distinct,
is 20 nm in diameter, and is helical-shaped, the pitch of helix is 5 nm (see Feldmann and Klenk, 1996; Jase-
nosky and Kawaoka, 2004; Hartlieb and Weissenhorn, 2006).
The viral genome is coding for structural and non-structural proteins (VPs). The core of the virion consists
of the RNA genomic molecule, of the nucleoprotein (NP) that binds the genomic RNA, and of the nucleocap-
sid viral protein 30 (VP30). They are linked by matrix viral proteins 24 and 40 (VP24 and VP40, respectively)
to the inner surface of the lipid bilayer of the viral envelope. The viral protein 35 (VP35) and the viral poly-
merase L (L) are also present in the core of the virion. The envelope glycoprotein GP, anchored to the viral
bilayer, forms the viral spikes driving host recognition (Fig. 2). Lipids are present and are located in the enve-
lope. The composition of viral lipids and host cell membranes are similar. The lipids are of host origin and are
derived from plasma membranes (see Takada and Kawaoka, 2001; Jasenosky and Kawaoka, 2004; Hartlieb
and Weissenhorn, 2006).
Comparison of Filoviridae genomes with other Mononegavirales demonstrates a similar structure and sug-
gest comparable mechanisms of transcription and replication (Fig. 2). However, comparative sequence anal-
yses of single genes indicate that Filoviridae are phylogenetically quite distinct from other families of the order
Mononegavirales (see Feldmann and Klenk, 1996; Jasenosky and Kawaoka, 2004; Hartlieb and Weissenhorn,
2006).
The genome constitutes 1.1% of the virion by weight. The genome is not segmented and consists of a single
molecule of linear, negative-sense ssRNA. The Ebolavirus and Marburgvirus genome consists of a single
about 19 kb strand of negative-sense RNA (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?CMD=
search&DB=pubmed). The genome cannot be transcribed or copied by host-cell enzymes, all the molecular
pattern required for viral replication is carried within the virion. Transcription begins at the 3 0-end and pro-U
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Fig. 2. Zaire ebolavirus. (Panel A) Arrangement of the seven filovirus genes along the single stranded negative-sense RNA genome.
Vertical lines indicate the intergenic regions (IR). (Panel B) Structure of a filovirus virion. (Panel C) Scanning electron micrograph of
Ebola virus-infected cell showing numerous virions on the cell surface. Modified from Mahanty and Bray (2004) and http://
www.ncbi.nlm.nih.gov/ICTVdb/Images/Murphy/ebola_cell.htm.
Please cite this article in press as: Ascenzi, P. et al., Ebolavirus and Marburgvirus: Insight the Filoviridae family, Mo-
lecular Aspects of Medicine (2007), doi:10.1016/j.mam.2007.09.005
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duces from seven to nine individual mRNAs. Nucleotide sequences at the 3 0-terminus are complementary to
similar regions on the 5 0-end. The 5 0-end of the negative-sense strand does not have a covalently attached ter-
minal protein. Moreover, the 5 0-end of the genome does not have cap. The 3 0-terminus has conserved nucle-
otide sequences (leader), in genera of same family. Furthermore, the 3 0-terminus has no poly(A) tract. The
single coding ssRNA may give the transcriptional information for three forms of the envelope glycoprotein
differing in length (i.e., three distinct mRNAs). Intergenic regions contain initiation and termination signals
(see Feldmann and Klenk, 1996; Jasenosky and Kawaoka, 2004; Mahanty and Bray, 2004; Ecker et al.,
2005; Ndayimirije and Kindhauser, 2005; Hartlieb and Weissenhorn, 2006).
The amino acid identity within Ebolaviruses ranges between 55% and 80%. The amino acid identity within
Ebolaviruses and Marburgvirues ranges between 24% and 46%. Strikingly, the amino acid identity between
Ebolaviruses and Marburgviruses VP40, is 25% only (Table 2). This agrees with distinct mechanisms of entry
of Marburgvirus and Ebolavirus despite causing similar diseases (see Chan et al., 2000).U
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OTable 2Amino acid sequence identity within Ebolaviruses and Marburgvirusa
Zaire ebolavirus Reston ebolavirus (%) Sudan ebolavirus (%) Lake Victoria marburgvirus (%)
Protein NP
Zaire ebolavirus – 67 67 38
Reston ebolavirus – 66 35
Sudan ebolavirus – 36
Lake Victoria marburgvirus –
Protein VP35
Zaire ebolavirus – 66 67 31
Reston ebolavirus – 67 32
Sudan ebolavirus – 31
Lake Victoria marburgvirus –
Protein VP40
Zaire ebolavirus – 75 75 25
Reston ebolavirus – 80 24
Sudan ebolavirus – 27
Lake Victoria marburgvirus –
Protein GPb
Zaire ebolavirus – 57 55 28
Reston ebolavirus – 60 26
Sudan ebolavirus – 27
Lake Victoria marburgvirus –
Protein VP30
Zaire ebolavirus – 68 69 29
Reston ebolavirus – 64 28
Sudan ebolavirus – 29
Lake Victoria marburgvirus –
Protein VP24
Zaire ebolavirus – 81 74 36
Reston ebolavirus – 75 34
Sudan ebolavirus – 34
Lake Victoria marburgvirus –
Protein L
Zaire ebolavirus – 73 73 46
Reston ebolavirus – 73 46
Sudan ebolavirus – 46
Lake Victoria marburgvirus –
a Amino acid sequences (from http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?CMD=search&DB=protein) were selected by BLAST
(from http://www.ncbi.nlm.nih.gov/BLAST) and aligned by ClustalW (from http://www.ebi.ac.uk/clustalw/index.html).
b Only protein GP of the Ivory Coast ebolavirus has been sequenced. The identity of the protein GP of the Ivory Coast ebolavirus within
Ebolavirus and Marburgvirus ranges between 64% and 28%.
Please cite this article in press as: Ascenzi, P. et al., Ebolavirus and Marburgvirus: Insight the Filoviridae family, Mo-
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2.2. NP protein
The central core of Ebolavirus and Marburgvirus consists of the ssRNA genomic molecule and its associ-
ated (nucleo)proteins (see Mahanty and Bray, 2004). NP contributes to virus nucleocapsid assembly and bud-
ding. The nucleocapsid structure of Ebolavirus appears to be composed of left-handed helices spaced at short
intervals, which is structurally consistent with other non-segmented negative-strand RNA viruses (see Huang
et al., 2002; Licata et al., 2004; Noda et al., 2005; Noda et al., 2007).
Both the N- and C-termini of NP (amino acid residues 2–150 and 601–739, respectively) of Ebolavirus NP
are important for NP–NP interaction, for the formation of NP tube structures, and for the incorporation of
NP into VLPs. The Ebolavirus NP tube forms a scaffold for the nucleocapsid-like structures. O-glycosylation
and sialylation of Ebolavirus NP are required for nucleocapsid assembly, the host enzymes involved and the
molecular mechanisms are still unclear. Moreover, the C-terminus of NP is important for nucleocapsid incor-
poration into virions. However, the region from amino acid residues 601–739 of NP was not required for
nucleocapsid formation or replication of the minigenome. Furthermore, the region from amino acid residues
451–600 of Ebolavirus NP is required for the formation of nucleocapsid-like structures and for replication of
the viral genome (see Licata et al., 2004; Watanabe et al., 2006; Noda et al., 2007). Lastly, Marburgvirus NP
alone is sufficient to form nucleocapsid-like structures (Kolesnikova et al., 2000; Mavrakis et al., 2002), which
suggests that the nucleocapsid structures of these two viruses are different (see Watanabe et al., 2006).
As a whole, given that NP is likely involved in all steps of viral replication after uncoating of the viral gen-
ome, a better understanding of the functional region(s) of this protein will provide insight into the Ebolavirus
life cycle and its pathogenicity (see Watanabe et al., 2006).
2.3. VP35 protein
Ebolavirus VP35, which plays an essential role in viral RNA synthesis, acts as a type 1 interferon (IFN)
antagonist (Basler et al., 2000). VP35 was packaged into budding VLPS, VP40, and VP35 being sufficient
for packaging an Ebolavirus minigenome RNA into VLPs (Johnson et al., 2006a,b). Moreover, VP35 inhibits
virus infection-induced transcriptional activation of the IFN regulatory factor-3-responsive mammalian pro-
moters (Basler et al., 2003) thus inhibiting also the transcriptional activation of type 1 IFN genes. The pro-
duction of an IFN antagonist might contribute to the pathogenicity of Ebolaviruses, much in the same
way as the NS1 protein of highly pathogenic influenza virus strain, another IFN antagonist, enhances the rep-
licative ability of influenza virus (Garcia-Sastre et al., 1998). It is well known that type 1 IFN production and
action represent an important arm of the innate immunity, that is also able to regulate the subsequent devel-
opment of the adaptive immune response. The innate immune system activation is the earliest response to
microbial entry and injury and in particular the disruption of the IFN system enhances susceptibility to many
microbial infections (Bose and Banerjee, 2006).
VP35 participates to spontaneous nucleocapsid assembly (Huang et al., 2002) and could be required for full
expression of virulence (Takada and Kawaoka, 2001). Moreover, VP35 counteracts the antiviral action of
IFN by its ability to suppress the pathway regulated by double-strand RNA-(dsRNA-)dependent protein
kinase PKR. The VP35 protein interferes with one or more components of the IFN pathways, which facilitates
rapid spread and dissemination of Ebola virus, therefore VP35 protein functions also at a step after IFN pro-
duction (see Feng et al., 2007).
Ebola virus is insensitive to IFN, although phosphorylation of STAT1 and STAT2, an early event of the
type 1 IFN signaling, was not affected (Jahrling et al., 1999; Kash et al., 2006). This raises the possibility that
Ebola virus blocks one or more steps after STAT phosphorylation, VP35 protein may be required to overcome
the antiviral action of IFN during Ebola virus infection. Furthermore, to inhibit the IFN system, VP35 coun-
teracts the activity of PKR, a key component in mediating the IFN-induced antiviral response (Gale et al.,
1998). In response to virus infection, PKR forms a homodimer and become phosphorylate on multiple Ser,
Thr, and Tyr residues (Gale et al., 1998; Dey et al., 2005; Su et al., 2006). These events convert PKR into
an active enzyme that phosphorylates also the a subunit of the eIF2a translation initiation factor. Suggesting
that in cells infected with Ebolavirus, VP35 may serve to block the activation of PKR and thereby abrogate
this ‘first line’ of host defense. Note that the inhibition of the PKR response by VP35 provides a favorablePlease cite this article in press as: Ascenzi, P. et al., Ebolavirus and Marburgvirus: Insight the Filoviridae family, Mo-
lecular Aspects of Medicine (2007), doi:10.1016/j.mam.2007.09.005
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environment for viral infection. Although the detailed mechanism by which VP35 acts is elusive, it is believed
that dsRNA produced in virus-infected cells is the activator of PKR. VP35 may act as a decoy of dsRNA thus
acting also in the inhibition of type 1 IFN production, that is triggered by more than one cellular dsRNA sen-
sors acting via the activation of IRF-3 transcription factor (see Feng et al., 2007).
The N-terminus of VP-35 is required to inhibit the PKR activity and the expression of b IFN gene. It is
noteworthy that the region containing amino acids 82–118 is predicted to form a coiled-coil domain, which
is required for the oligomerization of VP35 (Reid et al., 2005). This raises the possibility that oligomerization
of VP35 plays a role not only in blocking IFN production but also in the PKR response. The C-terminus of
VP35 is involved in blocking activation of IFN regulatory factor-3, which stimulates the synthesis of b-IFN
(Basler et al., 2003; Hartman et al., 2004; Reid et al., 2005; Cardenas et al., 2006; Hartman et al., 2006).
As a whole, the fact that the Ebolavirus VP35 interferes with PKR activity suggests that this function may
contribute to the pathogenesis of Ebolavirus infection (see Johnson et al., 2006a; Feng et al., 2007).
2.4. VP40 protein
Viral matrix proteins from negative-strand RNA viruses participate in the assembly of lipid-enveloped
viruses by providing a link between the surrounding membrane and the nucleocapsid structure (see Geis-
bert and Jahrling, 1995; Jasenosky and Kawaoka, 2004; Morita and Sundquist, 2004; Schmitt and Lamb,
2004; Hartlieb and Weissenhorn, 2006; Watanabe et al., 2006). VP40, the most abundant matrix protein in
Ebolavirus and Marburgvirus particles, is positioned beneath the viral bilayer to ensure the structural
integrity of the particle (Geisbert and Jahrling, 1995), plays an important role in virus assembly and bud-
ding (see Garoff et al., 1998; Hartlieb and Weissenhorn, 2006; Jasenosky and Kawaoka, 2004; Licata et al.,
2004; Morita and Sundquist, 2004; Schmitt and Lamb, 2004; Watanabe et al., 2006), and interacts prefer-
entially with bilayers with elevated levels of negatively charged phospholipids in vitro (Ruigrok et al.,
2000a). Moreover, VP40 is involved either in viral or host cell RNA metabolism during the replication
cycle as suggested by its capability of sequestering host RNA (Gomis-Ruth et al., 2003). Lastly, VP protein
is capable of eliciting protective immune responses to Zaire ebolavirus, this indicates that they may be
important components of a vaccine designed to protect humans from Ebola haemorrhagic fever (Wilson
et al., 2001).
The Zaire ebolavirus matrix protein VP40 is topologically distinct from all other known viral matrix pro-
teins (Dessen et al., 2000). Monomeric VP40 (Asn31-Lys326) is an elongated protein consisting of two
domains with unique folds connected by a flexible linker (Fig. 3, Panel A, and Table 3). The N-terminal
domain is folded into a b-sandwich consisting of six antiparallel b-strands arranged in two b-sheets of three
strands each. The C-terminal domain consists of one antiparallel triple-stranded b-sheet and an opposite set of
three b-strands which form a strongly bent b-sheet. In both domains, the b-strand shows a concave twist, and
an a-helix packs laterally with respect to the b-sheets. The matrix protein VP40 domains are not tightly packed
against each other, the interdomain region contains a zipper of hydrophobic residues. Most of the residues
corresponding to this hydrophobic stretch are conserved between Ebolavirus and Marburgvirus VP40
sequences (Dessen et al., 2000).
The VP40 undergoes dimerization by contacts within the N-terminal domains (Fig. 3, Panel B, and Table 3)
(the monomers forming the dimer are named A and B, according to Gomis-Ruth et al., 2003). The dimer is
stabilized by salt bridges from Glu160A to Arg148B and Arg151B, respectively. Moreover, polar interactions
are found between Trp95A and Gln184B. The stability of the dimer is enhanced by hydrophobic core inter-
actions (residues Trp95, Pro97, Phe161, Ile74, and Ile82 from molecules A and B) as well as residues Ala189–
Asp194 (from molecules A and B), which interact in an extended conformation on the outside of the ring with
a neighboring molecule (Gomis-Ruth et al., 2003). All polar residues except Glu160, which is substituted by
Asn, and all of the hydrophobic residues involved in the stabilization of the interface are conserved between
VP40 sequences from Ebolavirus and Marburgvirus (Dessen et al., 2000). The interface of the antiparallel
dimer coincides with the interface occupied by the N- and C-terminal domains in the closed monomeric con-
formation, and residues covered by both interfaces are approximately the same (Dessen et al., 2000; Gomis-
Ruth et al., 2003). This indicates that the C-terminal domain has to move away to allow the formation of the
dimer as suggested (Scianimanico et al., 2000).Please cite this article in press as: Ascenzi, P. et al., Ebolavirus and Marburgvirus: Insight the Filoviridae family, Mo-
lecular Aspects of Medicine (2007), doi:10.1016/j.mam.2007.09.005
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Fig. 3. Zaire ebolavirus VP40 protein structure. (Panel A) Ribbon diagram of VP40 monomeric structure. N-terminal and C-terminal
domain are shown in magenta and yellow respectively. Flexible loop regions without defined electron density maps are in red (PDB ID:
1ES6; Dessen et al., 2000). (Panel B) Ribbon diagram of the antiparallel dimer formed by the N-terminal domain of two VP40 monomers.
The two monomers are shown in magenta and green (PDB ID: 1H2D; Gomis-Ruth et al., 2003). (Panel C) Ribbon diagram of the ring
octameric structure of VP40 protein (subunits are in magenta and green). The RNA molecule, bound at the dimer–dimer interface, is
shown in ball-and-stick (PDB ID: 1H2D; Gomis-Ruth et al., 2003). Molecular graphics images were produced using the UCSF Chimera
package (Pettersen et al., 2004). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version
of this article.)
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Ebolavirus VP40 (Asn31-Asp194 and Asn31-Lys212) octamers have been detected in vivo (Gomis-Ruth
et al., 2003). However, VP40 hexamerization might play a role in Ebolavirus assembly, as reported for
HIV-1 and SIV (Dessen et al., 2000). To undergo octamerization, the VP40 N-terminal domain (Asn31-
Pro187) has to unfold allowing the formation of the dimer–dimer interface, of the RNA binding pocket,
and the interaction with cellular budding factors. Then, the C-terminal domain (Leu203-Lys326) moves out
of its position to facilitate the formation of the dimer and the association to the membrane. The octameric
ring structure is composed of four dimers, the N- and C-terminal ends are at the outer side of the ring
(Fig. 3, Panel C, and Table 3) (Gomis-Ruth et al., 2003).Please cite this article in press as: Ascenzi, P. et al., Ebolavirus and Marburgvirus: Insight the Filoviridae family, Mo-
lecular Aspects of Medicine (2007), doi:10.1016/j.mam.2007.09.005
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Table 3
Three-dimensional structures of Filoviridae proteins available on the RCSB Protein Data Banka
PDB Code Virus Protein Ref.
1ES6 Zaire ebolavirus VP40 Dessen et al. (2000)
1H2C Zaire ebolavirus VP40 Gomis-Ruth et al. (2003)
1H2D Zaire ebolavirus VP40 Gomis-Ruth et al. (2003)
1EBO Zaire ebolavirus GP Weissenhorn et al. (1998)
2EBO Zaire ebolavirus GP Malashkevich et al. (1999)
2I8B Zaire ebolavirus VP30 Hartlieb et al. (2007)
a Modified from Berman et al. (2000).
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et al., 2003) are dominated by hydrophobic interactions complemented with polar main chain contacts, includ-
ing hydrogen bonds between the amide of Gly141A and the carbonyl of Tyr171C, and the oxygen of Thr173A
and the amide of Gly139C. In addition, residues from the loop structure connecting b-strand 4 and a-helix 3
are sandwiched between two loop structures from a neighboring molecule, namely one connecting b-strands 1
and 2 and the other one bridging a-helix 4 with b-strand 6 (Gomis-Ruth et al., 2003).
A single-strand ribonucleotide segment 5 0-U-G-A-3 0 from the expression host Escherichia coli binds to
the dimer–dimer interface (Fig. 3, Panel C, and Table 3). Both ssRNA termini are pointing into the interior
of the pore, being accessible for bulk solvent and, putatively, for 3 0- and/or 5 0-elongated RNA molecules.
The main specificity of the observed trinucleotide binding resides in the central guanosine phosphate. The
guanine base interacts mainly with Arg134 and Phe125 of one protein chain. The backbone phosphate
group of G is linked via a double-headed salt bridge with Arg134 of the symmetry-related polypeptide,
while the sugar moiety contacts the protein main chain. Remarkably, all polar residues involved in the
RNA interaction are strictly conserved between Ebolavirus and Marburgvirus VP40 sequences and some
van der Waals contacts are substituted by conservative changes (Gomis-Ruth et al., 2003). Phe125Ala muta-
tion resulted in reduced RNA binding, and Arg134Ala mutation completely abolished RNA binding and
thus octamer formation.
In conclusion, RNA binding of VP40 and therefore octamer formation are essential for the Ebola virus life
cycle (Hoenen et al., 2005). The two oligomeric conformations play a central roles in the Ebolavirus life cycle,
the hexamer model suggests that the monomer–hexamer transition involves a conformational change(s) in the
N-terminal domain that is not evident during octamerization (Nguyen et al., 2005). The three different con-
formations of VP40 (monomeric, hexameric, and octameric) are the prime examples of how viral genomes
with a limited capacity can encode for protein conformations that probably exert different tasks (see Morita
and Sundquist, 2004; Schmitt and Lamb, 2004; Hartlieb and Weissenhorn, 2006).
2.5. GP proteins
Ebola virions possess a single surface transmembrane (TM) GP that plays a central role in virus attachment
and entry (by interaction of the GP signal peptide with cellular lectins), cell rounding, cytotoxicity, down-reg-
ulation of host surface proteins, and enhancement of virus assembly and budding (see Takada and Kawaoka,
2001; Chandran et al., 2005; Manicassamy et al., 2005; Alazard-Dany et al., 2006; Ba¨r et al., 2006; Han et al.,
2007; Manicassamy et al., 2007; Marzi et al., 2006a,b). Ebolavirus GP toxicity is contributed by a dynamin-
dependent protein-trafficking pathway and a ERK mitogen-activated protein kinease pathway (Sullivan et al.,
2005; Zampieri et al., 2007). However, GP is a component of the vaccine that has successfully protected non-
human primates against Ebolavirus haemorrhagic fever (Sullivan et al., 2003). Moreover, Zaire ebolavirus GP
represents a target for the cyanobacterial protein cyanovirin-N which impairs virus infection both in vitro and
in vivo (Barrientos et al., 2003).
Gene four of the Ebolavirus genome encode for the precursors of a soluble non-structural glycoprotein
(pre-sGP) and the structural TM glycoprotein (pre-GP) (see Dolnik et al., 2004; Falzarano et al., 2006).
Pre-sGP is the primary product and is processed by signalase and furin cleavage into the 291 amino-acid
long N-terminal fragment, sGP, and the 41 amino-acid long C-terminal fragment, D-peptide. Both sGP andPlease cite this article in press as: Ascenzi, P. et al., Ebolavirus and Marburgvirus: Insight the Filoviridae family, Mo-
lecular Aspects of Medicine (2007), doi:10.1016/j.mam.2007.09.005
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D-peptide are secreted from infected cells and sGP has been detected in the serum of infected individuals (see
Dolnik et al., 2004; Falzarano et al., 2006).
Similarly, pre-GP (a single chain precursor of 676 amino acids) is co- and post-translationally processed by
a signalase and furin into mature disulfide-linked fragments GP1 (Met1-Arg501) and GP2 (Glu502-Phe676).
Instability of the GP1–GP2 complex during intracellular transport and processing might lead to the release of
GP1. In addition, plasma membrane-associated GP1–GP2 is cleaved by a metalloprotease, which leads to the
shedding of an anchor-minus form, designated GP1–GP2DTM. While sGP shares the 295 N-terminal amino
acids with GP1, GP1–GP2DTM and GP1–GP2, its 28 amino acid C-terminus is unique due to RNA editing,
which allows expression of the TM glycoprotein GP1–GP2 and its related products (see Dolnik et al., 2004;
Falzarano et al., 2006).
While the two proteins share a considerable amount of primary sequence they have markedly different qua-
ternary structures, with sGP forming homodimers while GP1–GP2 forms trimers (see Dolnik et al., 2004; Fal-
zarano et al., 2006).
sGP is secreted as a disulfide-linked parallel homodimer, containing Cys53-Cys53 0 and Cys306-Cys306 0
disulfide bonds and five glycosylated sites. Disulfide bridges are critical for the proposed anti-inflammatory
function of sGP (see Falzarano et al., 2006).
GP1 is responsible for binding to cell-surface receptors, whereas GP2 is responsible for mediating mem-
brane fusion. Interestingly, GP1 is also shed in soluble form from infected cells (see Fields et al., 1996; Vol-
chkov et al., 1998; Takada and Kawaoka, 2001; Manicassamy et al., 2005). Interestingly, cleavage of GP by
endosomal cathepsin-B and -L triggers fusion and infection (see Chandran et al., 2005; Schornberg et al.,
2006).
The N-terminal region of GP1 is responsible for viral entry being implicated in cell receptor binding. More-
over, this GP1 region is involved in the proper folding and/or overall conformation of GP. Notably, sequence
comparison of the GP1 proteins suggests that the majority of the critical residues for GP folding and viral
entry identified in Ebola virus GP1 are conserved in Marburgvirus (Manicassamy et al., 2005).
The GP2 monomer contains a 44-residue N-terminal a-helix (Asp552-Gln595) followed by a 19-residue
link (Arg596-Asp614) and a short antiparallel a-helix (Trp615-Asp632) (Fig. 4, Panels A and C, and
Table 3). The Leu585-Ile610 sequence, containing the Cys601-Cys608 disulfide-bonded loop, is homolo-
gous to an immunosuppressive sequence found in many retrovirus TM subunits. The conformation of this
segment is very similar to that of the homologous sequence in the structure of the Murine Moloney Leu-
kemia virus TM subunit (Volchkov et al., 1992; Fass et al., 1996; Weissenhorn et al., 1998; Malashkevich
et al., 1999).
GP2 forms a trimer, each of the three polypeptide chains folds into a helical-hairpin conformation, in which
two antiparallel helices are connected by a loop region (Fig. 4, Panels B and D, and Table 3) The N-terminal
helices from each monomer form a central, three-strand coiled coil. This coiled-coil core includes approxi-
mately 35 residues (Leu561-Gln595) from each chain. Shorter C-terminal helices (Trp615-Asp629) pack in
an antiparallel manner into hydrophobic grooves on the surface of the coiled-coil core. In the loop region con-
necting the N- and C-terminal helices, a disulfide bridge between Cys601 and Cys608 links a short a-helix
(Thr600-Leu604) and a short 310-helix (Pro606-Ile610). Additionally, the loop region between the 310-helix
and the C-terminal helix (Glu611-Asp614) is in an extended conformation (Weissenhorn et al., 1998; Mala-
shkevich et al., 1999).
A trimeric structure is emerging as a general feature of many viral membrane-fusion proteins from the
Zaire ebolavirus, the orthomyxovirus influenza, the lentiviruses HIV-1 and SIV, and the paramxyovirus
SV5 (Malashkevich et al., 1999). Then, a model for Zaire ebolavirus fusion to host cell membrane has been
hypothesized based on the GP2 trimeric structure. The fusion peptide and the membrane anchor sequences
(belonging to GP2) extend toward one end of a thin rod-shaped molecule that could facilitate close apposition
of the prefusion membranes. The receptor binding domain (represented by GP1) is attached at the opposite
end of the fusion protein rod, where it could be withdrawn from the site of fusion. In this conformation,
GP2 could both bridge viral and cell host membranes and facilitate their apposition to initiate membrane
fusion (Fig. 5) (Weissenhorn et al., 1998).
Lastly, GP was found to induce a pro-inflammatory response similar to that of LPS (Martinez et al., 2007).
the Zaire ebolavirus GP2 trimeric structure may assist in the discovery of agents that prevent infection by Ebo-Please cite this article in press as: Ascenzi, P. et al., Ebolavirus and Marburgvirus: Insight the Filoviridae family, Mo-
lecular Aspects of Medicine (2007), doi:10.1016/j.mam.2007.09.005
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Fig. 4. Zaire ebolavirusGP2 protein structure. (Panel A) Ribbon diagram of hybrid monomeric GP2 (PDB ID: 1EBO; Weissenhorn et al.,
1998). (Panel B) Ribbon diagram of hybrid trimeric GP2 (subunits are in magenta, green, and yellow) (PDB ID: 1EBO; Weissenhorn et al.,
1998). (Panel C) Ribbon diagram of monomeric GP2. The N-terminal helix is shown in red. The C-terminal helix is shown in green. The
immunosuppressive motif region in oncogenic retroviruses (in magenta) is formed by a short a-helix and a short 310-helix. The loop regions
between the 310-helix and the C-terminal helix and between the short a-helix and the N-terminal helix are in cyan. Disulfide bridges are
represented in ball-and-stick (in yellow) (PDB ID: 2EBO; Malashkevich et al., 1999). (Panel D) Ribbon diagram of trimeric GP2. For
details, see panel C (PDB ID: 2EBO; Malashkevich et al., 1999). Molecular graphics images were produced using the UCSF Chimera
package (Pettersen et al., 2004). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version
of this article.)
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la virus. Indeed, synthetic peptides corresponding to the C-terminal helices of the trimeric structures in HIV-1
or in paramyxoviruses are inhibitors of entry by those viruses (Malashkevich et al., 1999).
2.6. VP30 protein
The Ebolavirus genome encodes for several proteins which are necessary for replication and transcription
of the viral RNA. Ebolavirus uses a unique transcription stratgey based on the activity of VP30, which is
essential for the activation and modulation of the synthesis of viral RNA. In fact, VP30 was shown to actPlease cite this article in press as: Ascenzi, P. et al., Ebolavirus and Marburgvirus: Insight the Filoviridae family, Mo-
lecular Aspects of Medicine (2007), doi:10.1016/j.mam.2007.09.005
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Fig. 5. Hypothetical model for the Zaire virus membrane fusion mechanism. Before fusion, viral GPs projects the receptor-binding
domains GP1 towards the cellular membrane. Suddenly, a conformational change of trimeric GP2 extends the N-terminal fusion peptides
towards the cellular membrane. Then, the outer layer of the fusion has assembled, the N-terminal fusion peptides (F) and the C-terminal
transmembrane anchors (A) lie near each other at a site of close apposition of the prefusion membranes. Flexible links between the rod and
the fusion peptide as well as the transmembrane anchors (A) allow variable orientations of the rod with respect to the two membranes. The
presence of a second GP protein system indicates how such trimers might aggregate at their hydrophobic ends at initial sites of fusion.
NGP1, GP1 N-terminal; NGP2, GP2 N-terminal. Modified from Weissenhorn et al. (1998).
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by stabilizing nascent RNA. RNA transcription activation depends strongly on the VP30 concentration and
phosphorylation state. VP30 binds NP, allowing incorporation into VLPs. Furthermore, VP30 may represent
a drug target, small-molecule inhibitors may interfere with VP30 homohexamerization preventing VP30 action
(see Mu¨hlberger et al., 1999; Weik et al., 2002; Hartlieb et al., 2003, 2007; John et al., 2007).
Self-assembly of VP30 is essential for viral transcription and propagation. The C-terminal domain of the
VP30 monomer folds into a compact core helical arrangement consisting of six helices. A seventh helix
reaches over to the neighboring monomer by a long linker, allowing both monomers to pack head to head,
with no significant structural similarity to known protein structures (Fig. 6, Panel A, and Table 3). The
dimerization interface covers about 3.727 A˚2. The majority of the contacts are polar interactions between
side-chain atoms and C-a backbone amides and carbonyls predominantly between the loop region connect-
ing helices 6 and 7 that nestles into a grove on the neighboring monomer made up by helices 1 and 2
(Fig. 6, Panel B, and Table 3). Since the dimerization is mainly achieved by domain swapping of helix 7,
the displacement of helix 7 may be sufficient to modulate VP30 homodimerization (i.e., to disrupt the dimer-
ization observed in the VP30 C-terminus and to allow other VP30 conformers). The conservation of these
interactions indicates that both Ebolavirus and Marburgvirus VP30 can form such VP30 dimers (see Hart-
lieb et al., 2007).
The VP30 homodimer might be the building block for the homohexameric active form of VP30 detected
in vitro and in infectious Ebolavirus particles. Essential for homooligomerization of VP30 is a region spanning
amino acids Ser94-Val112. Within this region, the Leu100-Leu101-Leu102-Leu103 sequence is of critical
importance. A second homooligomerization domain is composed of the C-terminal half of VP30 (see Hartlieb
et al., 2003, 2007).
The VP30 key amino acids involved in RNA binding map to residues 26–40, a region rich in Arg residues.
To modulate transcription, VP30 acts in trans with a RNA secondary structure upstream of the first transcrip-
tional start site (John et al., 2007).
NP binding occurs at two VP30 regions, namely a basic cluster around Lys180 and Glu197. VP30-NP rec-
ognition may be splitted into two functions. VP30 interacts loosely by its N-terminal domain with NP-RNA
helical-coil structures that are transcription-competent, without being released in VLPs. However, the inter-
action of packaged NP-RNA nucleocapsid complexes with the intact VP30 C-terminal domain allow to be
transported to the site of assembly and incorporated into VLPs (Hartlieb et al., 2007).
At catalytic concentrations, VP30 activates Ebolavirus transcription. In contrast, transcription activity is
suppressed with increasing VP30 concentration. Therefore, an equilibrium between activating and non-acti-
vating forms of VP30 might regulate Ebolavirus transcription activity and may control the balance of tran-Please cite this article in press as: Ascenzi, P. et al., Ebolavirus and Marburgvirus: Insight the Filoviridae family, Mo-
lecular Aspects of Medicine (2007), doi:10.1016/j.mam.2007.09.005
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Fig. 6. Zaire ebolavirus VP30 protein structure. (Panel A) Ribbon diagram of the C-terminal domain of the VP30 monomer shown in
magenta (PDB ID: 2I8B; Hartlieb et al., 2007). (Panel B) Ribbon diagram of the C-terminal domain of the VP30 dimer shown in magenta
and green (PDB ID: 2I8B; Hartlieb et al., 2007). H7 indicates the a-helix 7. Molecular graphics images were produced using the UCSF
Chimera package (Pettersen et al., 2004). (For interpretation of the references to colour in this figure legend, the reader is referred to the
web version of this article.)
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scription and replication. Furthermore, phosphorylation of VP30 (which takes place essentially at Ser res-
idues present in the Ser29-Ser46 region and at Thr52) regulates negatively transcription activation. How-
ever, it facilitate VP30 binding to NP inclusions (see Mu¨hlberger et al., 1999; Modrof et al., 2002;
Hartlieb et al., 2007).
Because of its essential function in viral transcription, VP30 is a potential candidate for antiviral therapy.
Dimerization of the VP30 C-terminal domain generates a 7 · 11 A˚ wide cavity whose interior is lined by
hydrophobic residues and its opening by conserved hydrophilic residues. Targeting this site by a small mole-
cule might inhibit transcription activation and thus productive infection of target cells. Furthermore, the olig-
omerization of VP30 is inhibited by the 25-mer peptide (E30pep-wt) derived from the Ebolavirus VP30 amino
acid sequence Gln91-Glu113 representing the homooligomerization domain. Thus, E30pep-wt seems to bind
efficiently to VP30 blocking both the protein homooligomerization and the viral replication. This suggests that
the inhibition of VP30 oligomerization may represent a target for Ebolavirus antiviral drugs (see Hartlieb
et al., 2003, 2007).Please cite this article in press as: Ascenzi, P. et al., Ebolavirus and Marburgvirus: Insight the Filoviridae family, Mo-
lecular Aspects of Medicine (2007), doi:10.1016/j.mam.2007.09.005
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The ability of VP30 to activate and modulate transcription is independent of its ability to bind to the
nucleocapsid complex by interaction with NP. Interestingly, zinc binding to VP30 (showing a unconven-
tional zinc-binding Cys3-His motif comprising Pro68-Leu95 amino acids) modulates viral transcription
without influencing the association to nucleocapsid-like particles (see Modrof et al., 2003; Hartlieb
et al., 2007).
Lastly, VP30 is capable of eliciting protective immune responses to Zaire ebolavirus indicating that it may
be an important component of a vaccine designed to protect humans from Ebola haemorrhagic fever (Wilson
et al., 2001).
2.7. VP24 protein
Ebolavirus VP40 is the primary matrix protein and the most abundant virion component. Although several
functions have been attributed to the Ebolavirus VP24, its precise role in viral replication remains ambiguous
and somewhat controversial. The VP24 was postulated to be a ‘minor matrix protein’ and a minor component
of virions or to function in viral uncoating. Moreover, VP24 appears to be essential for the formation of a
functional ribonucleoprotein complex. VP24 possesses structural features commonly associated with viral
matrix proteins and may have a role in virus assembly and budding. Lastly, the expression of VP24 results
in the inhibition of IFN-induced gene expression and in the inhability of IFNs to induce an antiviral state
(see Han et al., 2003; Jasenosky and Kawaoka, 2004; Licata et al., 2004; Hoenen et al., 2006b; Reid et al.,
2006; Watanabe et al., 2006).
2.8. L protein
The non-segmented negative-strand RNA viruses include some of the most problematic human, animal,
and plant pathogens (e.g., Ebolaviruses and Marburgvirus) (see Barr et al., 2002). Ebolavirus and Marburg-
virus gene transcription is catalyzed by protein L, a RNA-dependent RNA polymerase (Volchkov et al.,
1999). Sequence comparison of the Ebolavirus L proteins with several corresponding proteins of other
non-segmented, negative-strand RNA viruses, including Marburgvirus, indicates a close relationship
between filoviruses and members of the Paramyxovirinae (Volchkov et al., 1999). A combination of
sequence similarity and threading analysis suggests that the 2 0-O-ribose methyltransferase domain is
involved in capping of the viral mRNAs (Ferron et al., 2002). The key feature of transcriptional control
in the non-segmented negative-strand RNA viruses is polymerase entry at a single 3 0-proximal site followed
by obligatory sequential transcription of the linear array of genes. The levels of gene expression are primar-
ily regulated by their position on the genome. In addition, non-segmented negative-strand RNA virus gene
expression is regulated by cis-acting sequences that reside at the beginning and end of each gene and the
intergenic junctions (Barr et al., 2002).
All known eukaryotic and some viral mRNA capping enzymes transfer a GMP moiety of GTP to the 5 0-
diphosphate end of the acceptor RNA via a covalent enzyme-GMP intermediate to generate the cap structure.
In contrast, protein L appears to incorporate the GDP moiety of GTP into the cap structure of transcribing
mRNAs. As reported for Vesicular stomatitis virus (VSV), the Ebolavirus RNA-dependent RNA polymerase
(L protein) may catalyze the capping reaction by an RNA-GDP polyribonucleotidyltransferase activity, in
which a 5 0-monophosphorylated viral mRNA-start sequence is transferred to GDP generated from GTP
via a covalent enzyme-RNA intermediate (Ogino and Banerjee, 2007).
3. Virus assembly and budding
Negative-strand RNA virus particles are formed by a process that includes the assembly of viral compo-
nents at the plasma membranes of infected cells and the release of particles by budding (see Jasenosky and
Kawaoka, 2004; Morita and Sundquist, 2004; Schmitt and Lamb, 2004; Hartlieb and Weissenhorn, 2006;
Watanabe et al., 2006).
Although all the structural information to build a viral particle is encoded in the viral genome, filoviruses
(like other enveloped viruses such as HIV-1) hijack cellular protein machines to mediate assembly and bud-Please cite this article in press as: Ascenzi, P. et al., Ebolavirus and Marburgvirus: Insight the Filoviridae family, Mo-
lecular Aspects of Medicine (2007), doi:10.1016/j.mam.2007.09.005
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ding from cellular membranes. The recruitment of cellular factors serves potentially two major purposes.
Firstly, it needs to recruit factors that help to initiate the assembly process mediated by the matrix protein.
Secondly, recruitment of endosomal sorting complexes required for transport may be required for the last step
of the budding process, the release of the fully assembled virus particle from cellular membranes. Therefore,
selective employment of cellular proteins by enveloped viruses may provide specialized fine tuning accessories
for virus assembly and release (see Jasenosky and Kawaoka, 2004; Morita and Sundquist, 2004; Schmitt and
Lamb, 2004; Hartlieb and Weissenhorn, 2006; Watanabe et al., 2006).
Viral sequence motifs that are absolutely required for budding have been identified over the last decade,
they are termed late domains since affect a late step in budding. A number of late domain sequences have been
described to function in both positive- and negative-strand RNA virus assembly and budding. The late
domains serve as entry points into a network of proteins that normally functions in multi-vesicular body
(MVB) biogenesis. The protein network involved in MVB formation is implicated in membrane protein traf-
ficking from the Golgi and plasma membranes via the endosomal system to the lysosome for degradation (see
Martin-Serrano et al., 2004; Morita and Sundquist, 2004; Schmitt and Lamb, 2004; Hartlieb and Weissen-
horn, 2006; Watanabe et al., 2006).
VP40 buds from the cell surface forming VLPs. Ebolavirus VP40 contains two overlapping late domains
ProThrAlaProProGluTyr while Marburgvirus VP40 contains only the putative functional ProProProTyr
motif. Ebolavirus VP40 was shown to interact with Tsg101 via its ProThrAlaPro motif in vivo and in vitro with
both monomeric and oligomeric VP40; Tsg101 binds also ubiquitin (see Neumann et al., 2005; Johnson et al.,
2006a,b; Hartlieb and Weissenhorn, 2006).
The VP40 ProProProTyr motif mediates interactions with proteins that contain TrpTrp domains, such as
ubiquitin ligases. The ProProGluTyr motif was shown to interact with TrpTrp domain 3 of human Nedd4
in vitro, which requires the oligomeric ring-like conformation of VP40. The TyrPro(X)n Leu motif mediates
binding to protein ALIX/AIP1 that itself interacts with Tsg101 (see Fisher et al., 2007). It was long speculated
that ubiquitin plays a role in assembly and budding since ubiquitin is incorporated into retroviral particles (see
Harty et al., 2000; Noda et al., 2002; Licata et al., 2003; Panchal et al., 2003; Gruenberg and Stenmark, 2004;
Morita and Sundquist, 2004; Jasenosky and Kawaoka, 2004; Schmitt and Lamb, 2004; Bieniasz, 2006; Hart-
lieb and Weissenhorn, 2006; Watanabe et al., 2006; Urata et al., 2007).
The presence of intact late domains is required for the efficient release of VP40-containing VLPs albeit some
VP40 release takes place in the absence of late. Furthermore, Ebolavirus VP40 late domains are not required
for virion production in cell culture. This poses the question as to whether yet other unknown sequences in
VP40 are implicated in the assembly and budding process (see Hartlieb and Weissenhorn, 2006).
VP40 reveals mostly plasma membrane targeting, including lipid raft microdomain localization. Further-
more, VP40 interacts with nucleocapsid structures and endosomal membranes in Ebolavirus- and Marburg-
virus-infected cells. This suggests that VP40 is transported through the retrograde late endosomal pathway
en route from the endosome to the plasma membrane (see Jasenosky et al., 2001; Hartlieb and Weissenhorn,
2006).
The envelope of filoviruses is decorated by the trimeric surface protein GP, a type I TM protein, which
mediates cell entry (see Schibli and Weissenhorn, 2004). Two C-terminal acetylated-Cys residues (between
the TM region and the short cytoplasmic region) may play a role in a postulated interaction with the matrix
protein VP40 (see Hartlieb and Weissenhorn, 2006). Note that in Marburg virus-infected cells, GP localizes to
MVBs, which are enriched in VP40. This suggests that GP and VP40 are transported together to the site of
budding at the plasma membrane. In addition, such a co-localization is also consistent with virus budding into
endosomal structures (see Kolesnikova et al., 2004a,b). Like VP40, GP is targeted to lipid raft microdomains
in the plasma membrane. The co-expression of VP40 and GP supports and enhances the efficiency of VP40-
and GP-containing VLP formation, which is morphologically indistinguishable from infectious Ebola virus
(see Jasenosky et al., 2001; Bavari et al., 2002; Noda et al., 2002). Interestingly, VLP-containing VP40 and
GP have been shown to provide protection from filovirus infection upon VLP immunization (see Warfield
et al., 2004).
Expression of NP, the major determinant of the nucleocapsid (see Huang et al., 2002; Licata et al., 2004;
Noda et al., 2005, 2007), in mammalian cells leads to the formation of intracellular inclusion bodies, which are
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budding activity of VP40 suggesting an NP–VP40 interaction (Licata et al., 2004). Although VP40 interacts
with NP-containing nucleocapsids, VP40 and NP do not co-localize in MVBs, indicating that different forms
or conformations of VP40 pass by the MVB pathway and associate with nucleocpasids (Kolesnikova et al.,
2004a,b). Although it is currently not known how the assembled nucleocapsids leave the site of inclusion
bodies, it might involve the cellular cytoskeleton and VP40 interactions with microtubules (Ruthel et al.,
2005). Furthermore, NP is highly phosphorylated at its C-terminus, which might play a role in regulating
either RNA–protein or protein–protein interactions (see Licata et al., 2004; Noda et al., 2007). Not only
NP, but also VP35 is packaged within VP40 VLPs (see Licata et al., 2004; Hartlieb and Weissenhorn,
2006; Johnson et al., 2006a,b).
Although VP24 is implicated in the nucleocapsid assembly (see Huang et al., 2002; Han et al., 2003; Jase-
nosky and Kawaoka, 2004; Licata et al., 2004; Hoenen et al., 2006b; Reid et al., 2006; Watanabe et al., 2006),
it might be either important for the assembly of transport competent nucleocapsids or the association of nucle-
ocapsids with the transport machinery or in the targeting of the nucleocapsids to the budding sites containing
GP and VP40 (Bamberg et al., 2005; Kolesnikova et al., 2004b).
Very recently, the influence of calcium/calmodulin on budding of Ebola VLPs has been reported. The
mechanism of calcium/calmodulin-mediated inhibition of Ebola VLP budding may involve the Ras/Raf/
MEK/ERK signaling pathway (Han and Harty, 2007).
As a whole: (i) the transport of the matrix protein VP40 to the plasma membrane occurs by the retrograde
late endosomal pathway via MVBs. Then, VP40 re-localizes the cellular budding machinery to the site of virus
assembly and budding. VP40 was also found in association with viral inclusions containing assembled nucle-
ocapsids, probably in a conformation different from the monomeric form such as the hexameric form or the
octamers in complex with RNA. (ii) GP expression follows the regular secretory pathway and localizes to the
late endosome, after proteolytic cleavage in the trans-Golgi network, and accumulates in MVBs together with
VP40. Both are thus co-transported to the site of assembly and budding. (iii) NP–RNA interactions are suf-
ficient for nucleocapsid assembly that recruits VP30, VP35, and L. Nucleocapsids accumulate in cellular inclu-
sions that co-localize with small amounts of VP40. These complexes are then transported to VP40-and GP-
containing MVBs and to the plasma membrane that leads to virus particle assembly and release (Fig. 7) (Hart-
lieb and Weissenhorn, 2006).U
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Fig. 7. Schematic illustration of distinct transport pathways of viral components to the site of assembly and budding. (Panel A) Transport
of VP40 along the retrograde late endosomal pathway. (Panel B) Transport of the glycoprotein GP along the regular secretory pathway.
(Panel C) Transport of nucleocapsids (NC) and assembly of viral particles containing NC, VP40, and GP. Both GP and VP40 are targeted
to lipid raft microdomains (LR) that serve as platforms for assembly. GP and VP40 expression induces either the release of GP containing
vescicles or VP40 containing filamentous VLPs (Panels B and C, respectively). ER, endoplasmic reticulum; MVB, multi-vesicular body.
TGN, trans-Golgi network. The figure was modified from Kolesnikova and Becker (2004).
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4. Filovirus infection
4.1. Epidemiology
Marburgvirus is named after the town in Germany where the first cases of filovirus infection were recog-
nised, and a filovirus first isolated, in 1967 (Table 1) (Siegert et al., 1967), when simultaneous outbreaks of
an acute severe haemorrhagic illness occurred in Marburg, Frankfurt, and Belgrade. The illness affected ani-
mal handlers and laboratory workers in three vaccine production facilities who had been exposed to blood,
organs or cell cultures from green (vervet) monkeys (Cercopithecus aethiops) imported from Uganda.
Twenty-five human primary cases (of whom seven died) were identified; a further case was later identified
by retrospective serology (Feldmann et al., 1996). There were six secondary cases; all had provided direct
patient care to a primary case. These included two junior doctors, who had needlestick injuries after taking
blood; a morgue attendant; a nurse, and the spouses of two of the patients, one of whom had contact with
‘soiled linen’ while caring for her partner, a vet who had autopsied five of the monkeys, and the other from
whose partner Marburgvirus was isolated from semen (see Martini et al., 1968; Martini, 1969; Stille et al.,
1968; Todorovitch et al., 1971; Hennessen et al., 1971).
In 1976, concurrent outbreaks of haemorrhagic fever occurred in Yambuku, northeastern Zaire (now Dem-
ocratic Republic of Congo), and in Nazara, Maridi and the surrounding areas in southern Sudan. Around 300
cases were identified in each outbreak; case fatality rates exceeded 50% (53% in Sudan, 88% in Zaire) (WHO,
1978a,b). In both Maridi and Yambuku, transmission was amplified within hospitals, through provision of
patient care without personal protective equipment, and, in the hospital in Yambuku, where most medicines
were given by injection, by the reuse of needles and syringes. The new filovirus isolated from samples from
patients in Zaire was named after the river Ebola, which runs through the area where the outbreak occurred
(Johnson et al., 1977). Later work showed that although the outbreaks overlapped in time, and population
movement between the two areas was common, the outbreaks had been caused by two antigenically distinct
types of Ebolavirus, Zaire ebolavirus and Sudan ebolavirus (Bowen et al., 1980; Richmond et al., 1983).
Reston ebolavirus was discovered in 1989, causing haemorrhagic fever in cynomolgus macaques (Macaca
fascicularis) exported from the Philippines, and held in primate quarantine centres in Virginia, Texas, and
Pennsylvania (CDCP, 1989, 1990; Jahrling et al., 1990). Seroconversion was documented in four animal han-
dlers (including one who cut himself while performing an autopsy on an infected animal), but was not asso-
ciated with any clinical illness (CDCP, 1990). Further introductions of the virus, all traced to the same export
breeding facility in Luzon, occurred in 1990 (USA), 1992 (Italy), and 1996 (USA) (WHO, 1992; CDCP, 1996;
Rollin et al., 1999; Miranda et al., 1999). The original source of infection has not been discovered. Reston ebo-
lavirus does not seem to cause haemorrhagic illness in humans, though the infection can be lethal for non-
human primates (CDCP, 1996; Takada and Kawaoka, 2001; Mahanty and Bray, 2004).
The fourth species of Ebolavirus, Ivory Coast ebolavirus, has been isolated from a human only once, in
1994, from a scientist who was repatriated to Switzerland after developing a severe acute illness, with fever
and rash, unresponsive to antimalarial drugs, but without haemorrhagic signs, a few days after performing
an autopsy on a wild chimpanzee from the Tai National Park that had died from a haemorrhagic illness
(Formenty et al., 1999). The virus was also identified in fixed tissue from the chimpanzee (Le Guenno
et al., 1995).
Between 1967 and 1994 only seven cases of Marburg haemorrhagic fever (three sporadic cases in expatriate
travellers in rural Africa, associated with an additional three secondary cases, and a laboratory acquired infec-
tion in Russia) (Gear et al., 1975; Smith et al., 1982; Nikiforov et al., 1994; Johnson et al., 1996) and four
Ebola haemorrhagic fever incidents (Heymann et al., 1980; Le Guenno et al., 1999; Baron et al., 1983; Georges
et al., 1999) were reported. Then, in 1995, a hospital-amplified outbreak of Zaire ebolavirus occurred in Kikwit
in the Democratic Republic of Congo (formerly Zaire) (Khan et al., 1999). The outbreak had smouldered for
four months, misdiagnosed clinically as bacterial dysentery, and attracted the attention of the national author-
ities only after the deaths of a cluster of health care workers infected while assisting, largely unprotected from
exposure, at the laparotomies performed on an infected laboratory technician thought to have an acute sur-
gical abdomen. The Kikwit outbreak attracted intense, and unexpected, media attention, and lessons learned
from the outbreak led to a reorganization of the international response to infectious disease emergencies (Hey-Please cite this article in press as: Ascenzi, P. et al., Ebolavirus and Marburgvirus: Insight the Filoviridae family, Mo-
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mann et al., 1999). In the last five years, nine outbreaks of filovirus infection have occurred in Uganda, Gabon,
Republic of the Congo, Democratic Republic of Congo, and Sudan (Arthur, 2002; Pourrut et al., 2005; http://
www.who.int/csr/don/2004_08_07/en/index.html). These include the largest Ebolavirus outbreak yet recorded
(425 cases, 83% mortality), centered on Gulu in Uganda in 2000–2001, where initial cases again passed unde-
tected and transmission was amplified within hospitals (WHO, 2001; Okware et al., 2002), the Marburgvirus
outbreak around Durba in northeastern Democratic Republic of Congo in 1998–2000, where many of the
cases were young men who worked in the local gold mine (the main source of paid employment), and the over-
all case-fatality rate was 83% (128/154) (WHO, 1999; Bausch et al., 2003), and the 2004–2005 outbreak of
Marburgvirus infection in Uige province in Angola (374 cases, 88% mortality), where transmission was ampli-
fied by unsafe injections in health care centres, private clinics, and in self-treatment at home (Ndayimirije and
Kindhauser, 2005; Peters, 2005; http://www.who.int/csr/don/2005_08_24/en/index.html).
Human filovirus infections are generally regarded as zoonoses, although their natural reservoirs remain
unknown and, in the case of Sudan ebolavirus, a link with an animal species has not been clearly established.
Postulated reservoirs have included plants, arthropods, reptiles, small mammals (e.g., bats and rodents) (Pour-
rut et al., 2005); ecological niche modelling, based on the geographical distribution of reported human filovi-
rus infections, is now being used to identify candidate taxa for priority investigation (Peterson et al., 2004a,b).
The recent outbreaks of Zaire ebolavirus in Gabon and the Republic of the Congo have been linked, epide-
miologically and virologically, with an epizootic in great apes and other animals that has led to a rapid decline
in gorilla and chimpanzee populations, and damaged a developing eco-tourism industry (Leroy et al., 2004;
Pourrut et al., 2005). The epizootic may be progressing geographically, moving gradually through animal pop-
ulations, from Gabon into the Republic of the Congo. Genetic sequencing points to multiple introductions of
virus from an as yet unidentified reservoir. Surveillance of animal deaths has been used, with limited success,
to provide an early warning system for human outbreaks (Pourrut et al., 2005; Rouquet et al., 2005), and
attempts have been made to educate communities about the dangers of contact with, and consumption of
‘found’ animal carcasses (http://www.who.int/csr/disease/ebola/ebolacongofr.pdf). These have been the
apparent source of infection in several outbreaks, including those in Gabon in 1996 (when 18 children who
had helped to butcher and carry home the carcass of a dead chimpanzee that they had found in the forest
developed Ebola haemorrhagic fever), and in Gabon and the Republic of the Congo between 2001 and
2005, when index cases had handled gorillas, chimpanzees, or duiker (forest antelope), or their carcasses
(http://www.who.int/csr/disease/ebola/ebolacongofr.pdf). Animal to human transmission is assumed to have
followed the exposure of non-intact skin, or mucous membranes, to animal blood containing infective virus. It
is not known whether transmission can follow consumption of infected meat, though it might be expected that
the transmission risk from exposure to adequately cooked meat alone would be low (http://www.who.int/csr/
disease/ebola/ebolacongofr.pdf).
4.2. Pathogenesis
All filovirus infection of human and non-human primates are characterized by a similar illness that differs
only in severity and fatality rate. Existing data on the pathological mechanism involved in the disease have
been obtained by experimental infection of non-human primates and rodents as well as by clinical and labo-
ratory observation collected during the human outbreaks. The main pathogenic mechanism involved are: the
suppression of innate and adaptive immune response, the infection followed by death of a large number of
cells from a broad range of tissue, a strong inflammatory response, and the triggering of coagulopathy (see
Mahanty and Bray, 2004; Fisher-Hoch, 2005; Mohamadzadeh et al., 2007).
Filoviruses can infect and kill a large number of different cell types. This apparent lack of target specificity
is due to the wide distribution of cell-surface lectins that are involved in the binding of the viral surface GP.
The cell destruction due to the viral infection could result from the viral shut-down of several cellular process
as well as from the toxic effect of glycoproteins and other structural or matrix viral proteins. Moreover, Fil-
ovirus can affect immune system by a multiplicity of mechanisms. The interaction between viral and host pro-
teins can suppress certain innate antiviral responses. Ebolavirus VP35, in particular, has showed in several
cellular models the capacity to reduce IFN-a production by infected cells (Basler et al., 2000; Gupta et al.,
2001; Basler et al., 2003; Bosio et al., 2003). However, discordant findings have been reported by other authorsPlease cite this article in press as: Ascenzi, P. et al., Ebolavirus and Marburgvirus: Insight the Filoviridae family, Mo-
lecular Aspects of Medicine (2007), doi:10.1016/j.mam.2007.09.005
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that observed a large production in infected human macrophages, and high blood concentrations, in non-
human primates, of IFN-a (Hensley et al., 2002).
Macrophages, monocytes, and dendritic cells are early targets of viral infection. Infected macrophages can-
not restrict viral replication and produce proinflammatory cytokines, chemokines, and tissue factors. These
soluble products can attract additional target cells, induce vasodilatation, increase vascular permeability
and trigger disseminated intravascular coagulation. Infected dendritic cells also secreted proinflammatory
mediators and are impaired in their activity of antigen presenting cells. In addition, massive ‘bystander’ apop-
tosis of natural killer and T cells has been observed in non-human primates and mice models (Bray and Geis-
bert, 2005). Indirect evidences that a similar effect occurs also in human beings have been obtained in study
carried out during a human outbreak, where markers of intravascular apoptosis have been detected in blood
samples from fatally infected patients but not from survivors (Baize et al., 2000).
Regarding the major mechanisms that underlie the typical vessel damage and coagulation disorder, infec-
tion of endothelial cells has been well documented in non-human primates, but is observed only one day after
the onset of disseminated intravascular coagulation and the endothelium remained relatively intact even at
terminal stages of disease (Geisbert et al., 2003). In vitro cultured human endothelial cells are highly permissive
to Ebolavirus replication but no significant cytopathic effects have been observed (Geisbert et al., 2003). These
data suggest that, likewise other negative-strand RNA virus, haemorrhagic effects are likely triggered by
immune-mediated mechanisms. It has been hypothesized that VPs too can directly participate in the induction
of endothelial cells damage. In particular, VLPs consisting of Ebolavirus VP40, GP1, and GP2 were able to
activate endothelial cells and induce a decrease in the barrier function. However, GP seems to posses an anti-
inflammatory role by inducing a recovery of endothelial barrier function (Wahl-Jensen et al., 2005).
5. Clinical features and management
Although genetically distinct, Marburgvirus and the Zaire, Sudan, and Ivory Coast species of Ebolavirus
cause similar human illnesses. After an incubation period of 5–7 days (range 2–21 days; possibly shortened by
high-inoculum exposure), there is an abrupt onset of non-specific prodromal symptoms: fever, headache,
severe malaise, myalgia, nausea, and vomiting, abdominal pain and diarrhoea (often bloody), sometimes
accompanied by signs of conjunctivitis or pharyngitis, or the development of a maculopapular rash towards
the end of the first week. Early in the second week, the disease either worsens dramatically, with signs of vas-
cular involvement and coagulopathy (ranging from mild ooze from venepuncture sites, easy bruising, gingival
bleeding, and epistaxis, to catastrophic haemorrhage, often gastrointestinal), dehydration, shock, multi-organ
failure, and death, or a slow recovery begins. Antiviral drugs are not effective, and management – maintenance
of fluid and electrolyte balance, analgesia, oxygen therapy, transfusion, and treatment of coagulopathy with
platelet and clotting factor concentrates and heparin – is wholly supportive. Co-existing infections (e.g.,
malaria) should be excluded, or, if this is not possible, treated presumptively using standard treatment
regimes. The differential diagnosis includes shigellosis, typhoid, meningitis, other haemorrhagic fevers (includ-
ing yellow fever), and non-infective causes of disseminated intravascular coagulation (see Martini et al., 1968;
Baron et al., 1983; Bwaka et al., 1999; Formenty et al., 1999; Takada and Kawaoka, 2001; Mahanty and Bray,
2004; Fisher-Hoch, 2005).
Zaire ebolavirus has been viewed as the most virulent of the filoviruses for humans, and Marburgvirus the
least virulent, but our understanding of filovirus virulence has been challenged by the recent outbreaks of Mar-
burgvirus in Democratic Republic of Congo and Angola, where mortality of over 80% has been reported,
comparable with that in outbreaks of Zaire ebolavirus in Yambuku (88%) and Kikwit (81%), higher than that
reported in outbreaks of Zaire ebolavirus (59–78%) in Gabon and Republic of the Congo, and more than three
times that (23%) in the European Marburgvirus outbreak in Europe. Some experts have suggested that the
effects of filovirus infection, which incapacitate innate immune response mechanisms, are such that recovery
would be unlikely even if intensive medical care were to be provided (Peters, 2005). However, in some out-
breaks in Africa, survival rates have tended to improve towards the end of the outbreak (Colebunders
et al., 2004; Guimard et al., 1999; Francesconi et al., 2003). It is not clear whether this is the result of the
improved care (intravenous fluids, protein-rich feeding, transfusion, presumptive use of antimalarials, and
antibiotics) made possible once the numbers affected fall and conditions become less chaotic; an artefactPlease cite this article in press as: Ascenzi, P. et al., Ebolavirus and Marburgvirus: Insight the Filoviridae family, Mo-
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caused by variations in case ascertainment, or a viral ‘passage’ effect, whereby viral virulence lessens with suc-
cessive generations of transmission. It is also now evident that asymptomatic infections can occur (Leroy et al.,
2000). Perhaps mortality rates are not determined solely by viral factors, and other factors, which might
include the effectiveness of rehydration, the patient nutritional status and haematological reserve, co-infection
with other pathogens (e.g., malaria and HIV), and bacterial superinfection are more important determinants
of survival than has been assumed. In this context, it is interesting that key social and economic indicators
(http://www.wfp.org/Country_Brief/Hunger_Map/map), including the reported prevalence of undernutrition
(Uganda, 5–19%; Gabon, 5–19%; Sudan, 20–34%; Democratic Republic of Congo, Republic of the Congo,
and Angola, all >35%) (http://www.unicef.org/sowc06/intro.html) to some extent parallel the differences in
reported mortality rates in filovirus outbreaks in these countries.
Virological confirmation of the diagnosis (by antigen capture ELISA, RT-PCR for viral RNA, and specific
IgG/IgM detection) (Ksiazek et al., 1992; Towner et al., 2004) requires the specialized expertise available only
in tertiary care level laboratory facilities. It therefore almost inevitably requires international referral of spec-
imens from initial cases, which may be challenging, as filovirus infections have tended to occur in remote
areas, often affected by conflict, where fuel shortages are common, transport links poor or absent, and where
healthcare facilities lack capacity even for the diagnosis of the most common infection, malaria. The networks
put in place for the global polio eradication program to ensure the rapid transport of specimens (http://
www.polioeradication.org) with maintenance of the reverse-cold chain, could, if sustainable, be used to
improve access to diagnostic testing. Once an outbreak has been confirmed, and external assistance provided,
mobile field laboratories can be deployed and used to provide rapid, on-site, virological confirmation, which
can be used to guide decisions about case management and isolation, and follow up of contacts. Progress has
also been made in developing techniques for testing specimens other than blood or serum, including oral fluid
samples and post-mortem skin snips (Zaki et al., 1999), which are less dangerous than blood to collect, to
transport, and to examine.
Cases are viraemic from the onset of symptoms, and become progressively more viraemic as disease pro-
gresses; early onset of high-level viraemia carries a poor prognosis (Towner et al., 2004). Person to person
transmission follows percutaneous (e.g., needlestick injury and unsafe injection) or mucocutaneous (exposure
of the eyes, nose or mouth) exposure, or exposure of non-intact skin to infected blood or body fluids (vomit,
feces, and urine), and therefore occurs most often in the context of providing care for a case, either in a health-
care setting or in the home, or when preparing the body for burial. Sexual transmission, during convalescence,
has been reported, but there is no carrier state. Transmission by small particle aerosols has been demonstrated
in animal models in the laboratory (Johnson et al., 1995), but there is no clear evidence that airborne spread
from person to person occurs.
6. Prevention and control
Outbreak control and prevention is not complex, at least in theory. It requires recognition of the illness,
early isolation of suspect cases, personal protective equipment (gloves, gowns, masks, and eye protection)
to prevent exposure of healthcare workers and other careers to blood and body fluids, and the training to
use it correctly, safe injections, effective follow up and management of contacts, human, safe, and culturally
appropriate burial of the dead, and community education and involvement, harnessing, when possible, exist-
ing local understandings of disease transmission and prevention. When these measures have been applied, out-
breaks of filovirus infection have usually been rapidly controlled (see Hewlett and Amola, 2003).
In practice, however, outbreak recognition is usually delayed, such that index cases are usually identified
retrospectively, unless cases recur at, or close to, the site of a previous outbreak. Reporting is hampered by
lack of training in surveillance and diagnosis, by poor communications systems and underfunding. The con-
tact of cases with the health care system is as likely to result in the amplification of the outbreak as in control
of transmission. Healthcare workers and other careers become infected because the personal protective equip-
ment and supplies of disinfectants taken for granted in well-resourced countries are often simply not available;
indeed, health centres may have to function without running water, electricity, or safe waste-disposal systems,
and with unpaid staff. An explosive increase in the number of cases can follow exposures through unsafe injec-
tions. Disposable needles and syringes, which cannot be sterilized effectively, are more likely to be re-usedPlease cite this article in press as: Ascenzi, P. et al., Ebolavirus and Marburgvirus: Insight the Filoviridae family, Mo-
lecular Aspects of Medicine (2007), doi:10.1016/j.mam.2007.09.005
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when supply is limited; a syringe may be filled with a drug and used to dispense injections to multiple patients,
or a vial of a drug intended for single-dose adult use used to treat multiple pediatric patients. Such practices
remain widespread, despite the recognition that they are also associated with transmission of hepatitis C, hep-
atitis B, and HIV (Kane et al., 1999). The perception that treatments given by injection are more powerful
than those which are not may have contributed to transmission of Marburgvirus in Angola, where home injec-
tions are so frequent that community campaigns targeted at reducing this practice are needed to control the
epidemic. Outbreaks of filovirus infections, and transmission of other bloodborne virus infections will con-
tinue to occur, and may, as demand for ‘western-style’ health care continues to grow, become more frequent,
unless health authorities at local, national and international level are prepared to pay more than lip service to
the precept that medicine should first do no harm, and invest in the effective implementation of injection safety
and infection control programs in public, private, and informal care settings (see Fisher-Hoch, 2005).
7. Filovirus therapy
There are few reports of treatment of human filovirus cases. Although convalescent serum from surviving
patients, extracorporeal blood treatment with haemosorbents and dialysis, equine anti-Ebola immunoglobu-
lin, and IFN have been used to treat human filovirus cases, their efficacy has never been convincingly demon-
strated (see Bray and Paragas, 2002; Bray and Pilch, 2006).
A number of steps in the filovirus replication pathway offer targets for antiviral therapy, such as blockade
of the virus receptor, prevention of membrane fusion, interference with genome transcription and replication,
inhibition of cellular enzymes (e.g., S-adenosylhomocysteine hydrolase), enhancement of innate antiviral
mechanisms, interference with viral maturation, assembly, budding, and release, modulation of the clinical
syndrome, and treatment with antiviral agents (see Bray and Paragas, 2002; Bray and Pilch, 2006).
Two distinct situations must be considered in developing specific treatments for filovirus infections. The
first is the need for post-exposure prophylaxis to deal with the accidental infection of a laboratory investigator
or of a health care worker during an outbreak. In such cases, the goal of therapy would be either to prevent
viral replication and dissemination or else to significantly slow its pace, providing time for antigen-specific
immune responses to mobilize and suppress the virus. The most experience in experimental animals has been
obtained with antibody therapy (e.g., anti-GP). IFN-a forms in use for the treatment of hepatitis C may also
be of value in retarding filovirus dissemination, IFN-inducers might also be of some benefit. S-adenosylhomo-
cysteine hydrolase inhibitors have received only limited clinical evaluation because of problems with toxicity.
The second situation concerns the treatment of patients who have progressed to symptomatic illness, this is a
far more daunting problem. Therapy for such cases is needed in order to reduce mortality in filovirus out-
breaks, but in practice it will be very difficult to evaluate any experimental form of treatment under the con-
ditions of an epidemic in Africa. Only a combination of agents with differing mechanisms of action,
implemented as quickly as possible after diagnosis, may be capable of reducing the mortality rate in a filovirus
outbreak (see Bray and Paragas, 2002; Hensley et al., 2005; Bray and Pilch, 2006). Lastly, filovirus epidemics
can be halted by isolating patients and instituting standard infection control and barrier nursing procedures
(see Jeffs, 2006) (See Table 4).
8. Filovirus vaccine
Since the occurrence of the first Marburgvirus and Ebolavirus outbreaks numerous attempt to develop an
effective vaccine has been made, however no licensed vaccines to prevent or treat this infection is currently
available. Nevertheless several vaccine candidates have been tested for their ability to protect against filovirus
challenge, with varying degree of success. As shown in Table 5, several viral preparations or proteins have
been investigated for their immunological potential in rodents and non-human primate models by using both
classical-, subunit-, DNA- and vector-based vaccination strategies (see Reed and Mohamadzadeh, 2007).
About classical vaccination strategies, complete protection in rodents was obtained by using 60Co-irradi-
ated but not formalin-inactivated Marburgvirus; inactivated whole virus preparation of Ebolavirus showed
only partial protection (see Hevey et al., 2001; Geisbert et al., 2002; Reed and Mohamadzadeh, 2007). The
same authors reported that rodents vaccinated with an attenuated Marburgvirus were partially protectedPlease cite this article in press as: Ascenzi, P. et al., Ebolavirus and Marburgvirus: Insight the Filoviridae family, Mo-
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Table 4
Reported cases and outbreaks of human filovirus infection, 1967–2005
Year Place Cases (n) Deaths (n) Mortality (%) Comment
Marburgvirus
1967a Marburg, Germany 23 5
9>>>>>>>=
>>>>>>>;
23
25 primary cases (7 fatal) in animal handlers/
laboratory workers in three vaccine production
facilities directly exposed to blood, organs or cell
cultures of vervet monkeys imported from Uganda 6
secondary cases had direct exposure to patients
blood
Frankfurt, Germany 6 2 Further case identified later by retrospective serology
(total = 32).
Belgrade, Yugoslavia 2 0 Source of infection in monkeys not identified
1975b Johannesburg, South
Africa
3 1 33 Male traveller in rural Zimbabwe, transferred to
South Africa, died, bite from unknown insect 6 days
before symptom onset
Companion and nurse infected during patient care,
survived
1980c Kenya 2 1 50 Index case (died) had travelled in rural Kenya,
including Kitum cave, Mount Elgon National Park.
Secondary case attempted resuscitation of index case
1987d Kenya 1 1 100 European Male 15th, recent visit to Kitum cave,
Mount Elgon National Park
1990e Russia 1 1 100 Laboratory acquired infection
1998–2000f Democratic Republic
of Congo
154 128 83 Durba and Watsa areas. Diagnosis confirmed on
doctor who raised alarm (and who died), and had
described similar outbreak of ’Durba syndrome’ in
1996. Initial cases were young men who worked in
local gold mine; in a serosurvey seropositives were
more likely to be miners, and to have received
injections than seronegatives. Ix suggested multiple
introductions of virus, but source not identified
2004–2005g Angola 374 329 88 Uige. Outbreak amplified by unsafe injections at
home, in hospital/private clinics, and by indigenous
healers
Zaire ebolavirus
1976h Zaire (now
Democratic Republic
of Congo)
318 280 88 First recognised case had travelled in forest,
purchased fresh antelope and.monkey meat, fever 4
days later treated with chloroquine injection in in
Yambuku, haemorrhagic signs 10 days after this.
Transmission in epicentre in Yambuku amplified by
reuse of needles and syringes in hospital and and
outpatient clinic, 11 of 17 medical staff died,
outbreak ended soon after hospital was closed
1977i Zaire (now
Democratic Republic
of Congo)
1 1 100 Fatal haemorrhagic illness in Female 9th, in Tandala
diagnosed retrospectively by serology
1994–1995j Gabon 49 29 59 First cases in three temporary gold-panning camps
(Mekouka, Minkebe, Andock) in deep rain forest;
anecdotal, but unconfirmed, reports of dead gorillas,
chimpanzees; later cases associated with hospital
treatment, traditional healing or caring for sick
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Table 4 (continued)
Year Place Cases (n) Deaths (n) Mortality (%) Comment
1995k Democratic Republic
of Congo
315 255 81 Centred on Kikwit. Index case charcoal burner
working in forest adjoining the city. Amplification in
two hospitals in the city; 25% cases healthcare
workers. Source of infection not identified. Initially,
cases diagnosed as dysentery
1996j Gabon 31 21 68 18 primary cases were children in Mayibout II who
had helped to butcher or carry home dead
chimpanzee found in forest; secondary cases
followed in family members and in Mayibout I and
Mvadi villages
1996–1997j Gabon 60 45 75 Booue. Index cases were hunters living in logging
camps in forest, one visited traditional healer, was
scarified, healer and some patients infected, disease
spread to Libreville, Lastourville and Johannesburg.
Viral antigen detected in chimpanzee
2001–2002l Gabon and Republic
of the Congo
124 97 78 Series of smaller outbreaks in border areas of Gabon
and Republic of Congo. Disease spread from index
cases in Mendemba (hunters who handled duiker
[antelope] carcass) to Mekambo and Makokou.
Other transmission chains began in Ekata (duiker
carcass), Olloba (gorilla carcass), Etakangaye
(chimpanzee carcass), Grand-Etoumbi (gorilla
carcass)
2002–2003m Republic of the
Congo
143 128 90 Initial cases in gold mining camp in Mvoula (spread
to Mbomo) linked to handling duiker carcass, and in
Yembelengoye, near Entsiami (spread to Kelle) to
handling gorilla carcass. 13 cases lab confirmed
2003m Republic of the
Congo
35 29 83 Mbomo and Mbandza; 16 cases lab confirmed. No
animal source identified, though wild boar carcass
handled
2005n Republic of the
Congo
12 9 75 Etoumbi and Mbomo; 1 case lab confirmed, others
epidemiologically linked, index case handled gorilla
carcass
Sudan ebolavirus
1976o Sudan 284 151 53 Nzara and Maridi areas; initial cases in workers in a
cotton factory in Nzara, main centre of local
employment.
1979p Sudan 34 22 65 Nzara and Maridi, ie same locality as 1976 outbreak,
initial cases again in cotton factory in Nzara
2000–2001q Uganda 425 224 53 Primary cases passed undetected, outbreak centred
in Gulu, with spread through transfer of cases to
Masindi and Mbarara. Amplified within hospitals by
lack of infection control, and within community by
case contact during home nursing and traditional
burial rites. Over 5000 contacts followed up
2004r Sudan 17 7 41 Yambio, south Sudan (close to Nzara and Maridi).
13 cases laboratory confirmed; some cases initially
thought to be EHF reclassified as measles after
testing
(continued on next page)
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Table 4 (continued)
Year Place Cases (n) Deaths (n) Mortality (%) Comment
Reston ebolavirus
1989s United States of
America
4 0 0 Illness in cynomolgus macaques exported from
Philippines and held in quarantine centres in Virginia
(Reston), Texas (Alice) and Pennsylvania
(Philadelphia); 4 animal handlers seroconverted, but
had no clinical illness
1990s United States of
America
0 0 NA Reintroduction of virus to quarantine centres in
Virginia and Texas via macaques from same export
centre in Philippines
1992t Italy 0 0 NA Virus introduced to quarantine centre in Siena;
macaques from export centre in Philippines involved in
earlier incidents
1996u United States of
America
0 0 NA Virus again detected in quarantine centre in Texas;
source centre in Philippines depopulated, export licence
revoked
Ivory coast ebolavirus
1994v Cote d’Ivoire 1 0 0 Ethologist performed autopsy on freshly dead
chimpanzee in Tai National Park. Repatriated to
Switzerland, rash and thrombocytopaenia but no frank
haemorrhage, recovered. Virus identified in chimpanzee
tissue also
Unspecific ebolavirus
1996w Russia 1 1 100 Laboratory acquired infection, Sergiyev Posad, Moscow
2004w Russia 1 1 100 Laboratory acquired infection after needlestick injury
while injecting guinea pig, Vector, Koltsovo, Siberia
2004w United States of
America
1 0 0 Needlestick injury while injecting mice with ’attenuated
virus’ in Fort Detrick; asymptomatic infection
a From Siegert et al. (1967), Martini et al. (1968), Stille et al. (1968), Hennessen (1971), Todorovitch et al. (1971) and Feldmann et al.
(1996).
b From Gear et al. (1975).
c From Smith et al. (1982).
d From Johnson et al. (1996).
e From Nikiforov et al. (1994).
f From WHO (1999) and Bausch et al. (2003).
g From Ndayimirije and Kindhauser (2005), Peters (2005) and http://www.who.int/csr/don/2005_08_24/en/index.html.
h From Johnson et al. (1977), WHO (1978a,b), Bowen et al. (1980) and Richmond et al. (1983).
i From Heymann et al. (1980).
j From Georges et al. (1999), Arthur, 2002 and Pourrut et al., 2005.
k From Bwaka et al. (1999), Guimard et al. (1999), Heymann et al. (1999), Khan et al. (1999) and Pourrut et al. (2005).
l From Arthur (2002), WHO, 2003a,b and http://www.who.int/mediacentre/factsheets/fs103/en/index1.html.
m From Arthur (2002), http://www.who.int/csr/don/2004_01_06/en/index.html and http://www.who.int/mediacentre/factsheets/fs103/
en/index1.html.
n From http://www.who.int/csr/don/2005_06_16/en/index.html and http://www.who.int/mediacentre/factsheets/fs103/en/index1.html.
o From WHO (1978a,b), Bowen et al. (1980) and Richmond et al. (1983).
p From Baron et al. (1983).
q From CDCP (2001b), WHO (2001) and Okware et al. (2002).
r From http://www.who.int/csr/don/2004_08_07/en/index.html.
s From CDCP (1989), CDCP (1990) and Jahrling et al. (1990).
t From WHO (1992).
u From CDCP (1996), Miranda et al. (1999) and Rollin et al. (1999).
v From Le Guenno et al. (1995) and Formenty et al. (1999).
w From http://www.who.int/mediacentre/factsheets/fs103/en/index1.html.
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Table 5
Summary of filovirus vaccine effortsa
Approach Immunogen Immunity Efficacy Concerns
Rodents Non-human
primates
Classical
Killedb Whole virus IgG+, low NT Varies Failed Potency, schedule, adjuvant, safety
Attenuatedc Whole virus IgG+ Failed Failed Safety
Subunit
Baculovirusd GP, GPDTM IgG+ Partial ND Potency, glycosylation
VLPe GP+VP40 IgG+, NT+, CD4+ Good ND Potency, schedule
DNA
Alonef GP, NP IgG+ Poor ND Potency, schedule
Prime/boost with
Adenovirusg
GP IgG+, no NT, CD4+ Good Good Schedule, potency
Vectored
Vacciniah GP, VP24 IgG+, low NT Poor Anti-vector immunity, safety, potency
VRP/VEEi GP, GP+NP, NP, VP35, VP30,
VP24
IgG+, no NT, CTL,
CD4+
Good Good Anti-vector immunity, potency, schedule, heterologous
viruses
Adenovirusj GP, GP+NP IgG+, CD8+ Good Good Anti-vector immunity, potency
VSVk GP IgG+, no NT, no CMI Good Good Safety
Parainfluenzal GP, GP+NP IgG+ Good Safety
ND, not determined.
a Modified from Reed and Mohamadzadeh (2007).
b From Lupton et al. (1980), Ignatyev et al. (1996) and Warfield et al. (2004).
c From Bray et al. (2001).
d From Hevey et al. (1997), Hevey et al. (2001) and Mellquist-Riemenschneider et al. (2003).
e From Bavari et al. (2002), Warfield et al. (2003), Swenson et al. (2004), Warfield et al. (2004), Swenson et al. (2005) and Warfield et al. (2005).
f From Vanderzanden et al. (1998), Mellquist-Riemenschneider et al. (2003) and Riemenschneider et al. (2003).
g From Sullivan et al. (2000).
h From Geisbert et al. (2002).
i From Pushko et al. (1997), Hevey et al. (1998), Pushko et al. (2000), Hevey et al. (2001), Wilson et al. (2001) and Olinger et al. (2005).
j From Sullivan et al. (2003).
k From Jones et al. (2005).
l From Bukreyev et al. (2006).
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by challenge with virulent Marburgvirus and the live vaccine, that had proven non-lethal in some strain of
guinea pigs, on the contrary proved fatal in 20% of animals from another guinea pig strain (see Hevey
et al., 2001; Reed and Mohamadzadeh, 2007).
Regarding vaccination strategies based on single or multiple filovirus proteins, most of the latest effort to
develop vaccines have examined the protective capacity of GP, alone (Sullivan et al., 2000; Hevey et al., 2001;
Rao et al., 2002; Riemenschneider et al., 2003; Mellquist-Riemenschneider et al., 2003; Jones et al., 2005;
Wang et al., 2006a,b) or in association with both NP or VP40 (Swenson et al., 2004; Warfield et al., 2004;
Swenson et al., 2005). The vaccine potential of other internal structural proteins has been investigated as well.
VP24, VP30, and VP35 expressed by using recombinant Venezuelan equine encephalitis (VEE) vectors, have
been shown to elicit some immunological response in rodents, but no single VP was able to confer complete
protection against lethal Ebolavirus and Marburgvirus challenges (Hevey et al., 1998; Wilson et al., 2001). Pre-
vious investigation on rodents vaccinated with Ebolavirus VPs expressed by an alternative vector, recombi-
nant Vaccinia, equally failed to elicit protective immunity (see Wilson et al., 2001). However, further
investigations are needed before that the information obtained from this studies could be safely used for
the development of a human vaccine. As a matter of fact, proof of vaccine concepts in rodent models may
not necessarily forecast success in non-human primates and, by inference, in humans. Several vaccination
strategies that were able to confer protective immunity to rodents, failed to protect non-human primates from
robust challenge with Ebolavirus (Geisbert et al., 2002). However, the full protection from homologous filo-
virus infection obtained in non-human primates by using vaccination strategies based on Marburgvirus VEE
replicons (Hevey et al., 1998), Ebolavirus adenovirus vectors (Sullivan et al., 2003), and Marburgvirus/Ebo-
lavirus VSV (Jones et al., 2005) supports the results obtained in rodent models indicating that filovirus GPs are
appropriate and perhaps sufficient components of vaccines, they can elicit both humoral and cellular specific
response. Anyway, also the more effective vaccine can elicit only protection against heterologous strains from
the same virus species, and ineffectual immune responses could be responsible of an immune-mediated exac-
erbation of disease progression in unprotected animal (see Swenson et al., 2005). Therefore a multivalent vac-
cine strategy is needed to obtain protection against all human pathogenic filovirus species (see Reed and
Mohamadzadeh, 2007).
Multivalent DNA vaccine for Zaire ebolavirus, Sudan ebolavirus, and Ivory Coast ebolavirus has been shown
to elicit a strong humoral response in rodents and protect animals against a lethal challenge with Zaire ebola-
virus (Sullivan et al., 2000). A multiagent DNA vaccine for anthrax, VEE, Marburgvirus and Ebolavirus pro-
tected only about an half of the rodents challenged with either Marburgvirus or Ebolavirus (Riemenschneider
et al., 2003). The possibility that multiagent immune protection could be elicited by using a VEE replicon-based
vaccination strategy has been investigated as well. The results indicated that immune protection against Lassa
and Ebolavirus could be developed in guinea pigs (see Pushko et al., 2001; Reed and Mohamadzadeh, 2007).
Although further investigation are needed and any positive results showed in rodents must obligatorily be
confirmed in non-human primate models, the whole of the knowledge so far collected encourage us to believe
that the development of a human vaccine is not so distant to be obtained (see Reed and Mohamadzadeh,
2007).
9. Filoviruses as biological weapons
The increased threat of terrorism necessitates an evaluation of the risk posed by various microorganisms as
biological weapons. This is especially important in the case of the filoviruses. Ebolavirus and Marburgviruses,
classified as Category A biowarfare agents, are considered as potential biological weapons because they pose a
threat as lethal pathogens and because their use by terrorists might result in extreme fear and panic (see Borio
et al., 2002; Bray, 2003).
An effective defense against filoviruses requires a comprehensive approach that includes the following ele-
ments: prevention of access to virus stocks, improved means of detection of deliberately induced disease out-
breaks, rapid medical recognition of the viral haemorrhagic fever syndrome, rapid laboratory identification of
filoviruses in patient specimens, prevention of person-to-person transmission, reliable decontamination proce-
dures, development of effective vaccines, and development of effective antiviral therapy (see Borio et al., 2002;
Bray, 2003).Please cite this article in press as: Ascenzi, P. et al., Ebolavirus and Marburgvirus: Insight the Filoviridae family, Mo-
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Although a variety of mechanisms are in place to protect the military and civilian populations of industri-
alized countries against infectious agents in food and water, it is impossible to provide them with a constant
supply of purified air. The most dangerous form of biological warfare exploits this vulnerability (Bray, 2003).
There are reports about research projects really carried out in Soviet Union (now Russia) to weaponize
Ebolavirus and Marburgvirus (CDCP, 2001a; Borio et al., 2002; http://cns.miis.edu/research/cbw/pos-
sess.htm). Using a monkey model, Soviet Union researchers have been able to demonstrate that also the inha-
lation of low concentration of infectious virus by aerosol is sufficient for the transmission of the disease
(Bazhutin et al., 1992). So the respiratory route of transmission of weaponized filoviruses will add to the well
known routes that characterized the way of viral spread in natural outbreaks (i.e., injection and direct con-
tacts) (CDCP, 2001a). Alternatively, non-aerosolized material could be used to produce infection by contam-
inating surfaces, foods or beverages (see Borio et al., 2002; Bray, 2003).
If an aerosol attack with a filovirus goes undetected, at least a week will elapse before the onset of the
first illnesses. By that time, no infectious virus will remain in the environment, and there will be no need
for surface decontamination. Even if an aerosol attack is detected while still in progress or is discovered
soon after completion, persons who have not actually inhaled the agent will be at negligible risk of infec-
tion from any residual aerosolized virus that might linger in the environment, since the few viral particles
that might adhere to skin, clothing or surfaces would degrade within hours through the action of UV light.
However, it would be prudent for people who may have been exposed to an aerosolized agent to take a
full body shower with soap and to wash their clothing in hot water with detergent (see Borio et al., 2002;
Bray, 2003).
Decontamination becomes a very important concern when virus-containing liquids or other materials are
present, either as body fluids from sick patients or as residues from liquid suspensions employed to carry out a
terrorist attack. Filoviruses may survive at room temperature in liquid or dried material for a number of days
(Belanov et al., 1996). Steam sterilization is the most effective method of inactivating filoviruses. For the dis-
infection of surfaces and objects that are contaminated with blood or other body fluids, but cannot be ster-
ilized by steam, the ‘Centers for Disease Control and Prevention’ recommends treatment with either a
1:100 dilution of household bleach or with any of the standard hospital disinfectants (see CDCP, 1995; CDCP,
1998; Bray, 2003).
Although some progress has been made in developing vaccines and antiviral drugs and terrorists might
have great difficulty acquiring a filovirus for use as a weapon, public perception of a threat of epidemic spread
could cause major social and economic disruption. A limited attack might thus achieve an impact out of pro-
portion to the actual number of illnesses and deaths (see Bray, 2003).
10. Conclusion and perspectives
Ebolavirus and Marburgvirus overwhelm host defenses and cause disease by disregulating and defeating
first the innate and then the adaptive immune systems of primates and humans. Ebola and Marburg haemor-
rhagic fevers appear as the result of accidental infection of human beings by agents that have evolved to sur-
vive in other animal species. In their reservoir hosts, filoviruses presumably cause mild, long-lasting, and
probably non-fatal illness.
If host responses are important in determining the outcome of filoviral infection, then improvement or cor-
rection of those responses should be an effective therapeutic strategy. The addition of other types of therapy to
block induction of increased vascular permeability and hypotension should also be beneficial. To elucidate
how some people are able to mobilize protective responses and survive filovirus infection, while others die
from overwhelming disease, study of the course of illness in patients in future outbreaks will be important.
Detection of cases of mild or asymptomatic filoviral infection will also be important because it will provide
the best means of identifying early host responses that can prevent development of severe disease.
The structural and functional characterization of Ebolavirus and Marburgvirus proteins as well as of filovi-
ral ssRNA is a prerequisite to develop vaccines and specific drugs. Most of the effort to develop vaccines have
examined the protective capacity of GP, alone or in association with both NP or VPs. The development of
vaccines and therapies against Ebola and Marburg haemorrhagic fever is mandatory since these filovirus
are considered as potential biological weapons.Please cite this article in press as: Ascenzi, P. et al., Ebolavirus and Marburgvirus: Insight the Filoviridae family, Mo-
lecular Aspects of Medicine (2007), doi:10.1016/j.mam.2007.09.005
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